A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 5,397 shares of SRPT stock, worth $613,746. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,397
Previous 6,331 14.75%
Holding current value
$613,746
Previous $1 Million 32.6%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$124.33 - $156.75 $116,124 - $146,404
-934 Reduced 14.75%
5,397 $674,000
Q2 2024

Jul 26, 2024

BUY
$113.33 - $163.85 $13,599 - $19,662
120 Added 1.93%
6,331 $1 Million
Q1 2024

Apr 24, 2024

BUY
$93.7 - $141.53 $306,117 - $462,378
3,267 Added 110.97%
6,211 $804,000
Q4 2023

Feb 09, 2024

BUY
$67.31 - $124.76 $10,365 - $19,213
154 Added 5.52%
2,944 $284,000
Q3 2023

Oct 24, 2023

BUY
$102.5 - $123.59 $205 - $247
2 Added 0.07%
2,790 $338,000
Q2 2023

Jul 13, 2023

BUY
$106.4 - $157.19 $319 - $471
3 Added 0.11%
2,788 $319,000
Q1 2023

May 11, 2023

BUY
$117.53 - $155.99 $134,101 - $177,984
1,141 Added 69.4%
2,785 $384,000
Q4 2022

Feb 08, 2023

SELL
$100.86 - $132.13 $47,101 - $61,704
-467 Reduced 22.12%
1,644 $213,000
Q3 2022

Oct 17, 2022

BUY
$75.71 - $119.24 $159,823 - $251,715
2,111 New
2,111 $233,000
Q1 2022

May 12, 2022

SELL
$63.15 - $90.42 $206,184 - $295,221
-3,265 Closed
0 $0
Q4 2021

Feb 03, 2022

SELL
$77.28 - $99.42 $66,847 - $85,998
-865 Reduced 20.94%
3,265 $294,000
Q3 2021

Nov 02, 2021

SELL
$65.97 - $92.48 $79,229 - $111,068
-1,201 Reduced 22.53%
4,130 $381,000
Q2 2021

Aug 10, 2021

BUY
$69.38 - $86.75 $25,323 - $31,663
365 Added 7.35%
5,331 $414,000
Q1 2021

May 07, 2021

BUY
$72.25 - $168.95 $114,155 - $266,941
1,580 Added 46.66%
4,966 $370,000
Q4 2020

Feb 04, 2021

SELL
$125.56 - $178.74 $90,026 - $128,156
-717 Reduced 17.48%
3,386 $577,000
Q3 2020

Oct 29, 2020

SELL
$127.12 - $172.34 $12,584 - $17,061
-99 Reduced 2.36%
4,103 $576,000
Q2 2020

Jul 27, 2020

SELL
$93.0 - $171.7 $80,259 - $148,177
-863 Reduced 17.04%
4,202 $673,000
Q1 2020

May 08, 2020

BUY
$82.38 - $131.64 $32,952 - $52,655
400 Added 8.57%
5,065 $495,000
Q4 2019

Feb 04, 2020

BUY
$76.53 - $135.58 $6,581 - $11,659
86 Added 1.88%
4,665 $601,000
Q3 2019

Nov 06, 2019

SELL
$72.81 - $156.91 $5,970 - $12,866
-82 Reduced 1.76%
4,579 $344,000
Q1 2019

May 08, 2019

BUY
$106.67 - $151.68 $52,801 - $75,081
495 Added 11.88%
4,661 $0
Q4 2018

Feb 05, 2019

SELL
$97.32 - $148.76 $216,731 - $331,288
-2,227 Reduced 34.83%
4,166 $454,000
Q3 2018

Nov 02, 2018

BUY
$115.31 - $161.51 $299,344 - $419,279
2,596 Added 68.37%
6,393 $0
Q2 2018

Aug 10, 2018

SELL
$71.74 - $153.69 $484,531 - $1.04 Million
-6,754 Reduced 64.01%
3,797 $0
Q1 2018

May 09, 2018

BUY
$54.02 - $82.27 $319,366 - $486,380
5,912 Added 127.44%
10,551 $0
Q4 2017

Feb 22, 2018

SELL
$47.64 - $56.75 $48,164 - $57,374
-1,011 Reduced 17.89%
4,639 $0
Q3 2017

Nov 07, 2017

BUY
$35.73 - $47.15 $201,874 - $266,397
5,650
5,650 $256,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $9.96B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.